colorectal cancer

[Nature Communications] Researchers showed that loss of ABHD5 promoted c-Met activation to sustain colorectal cancer stemness in a non-canonical manner.

[Biosplice Therapeutics, Inc.] Biosplice Therapeutics, Inc. announced the dosing of the first subject in a Phase Ib, open-label, multicenter, dose-escalation, dose expansion clinical trial of cirtuvivint in subjects with advanced solid tumors.

[Cancer Medicine] The authors provide a brief review based on the source, structural characteristics, mechanisms, biological functions of circular RNAs, and the relationships between colorectal cancer.

[Cellular Signalling] Scientists examined the regulatory effects of ZRANB1 on the maintenance of CSC properties and tumor growth in colorectal cancer.

[Oncogene] Scientists identified a S100A2/KPNA2 cotransport complex that transported the tumor-associated transcription factor NFYA in colorectal cancer.

[Signal Transduction and Targeted Therapy] Fusobacterium nucleatum induces different immune responses in colorectal cancer (CRC) with different microsatellite-instability statuses. Scientists investigated the effect of F. nucleatum on anti-PD-L1 therapy in CRC.